Role of aldosterone and mineralocorticoid receptor (MR) in addiction: A scoping review

Neurosci Biobehav Rev. 2023 Nov:154:105427. doi: 10.1016/j.neubiorev.2023.105427. Epub 2023 Oct 17.

Abstract

Preclinical and human studies suggest a role of aldosterone and mineralocorticoid receptor (MR) in addiction. This scoping review aimed to summarize (1) the relationship between alcohol and other substance use disorders (ASUDs) and dysfunctions of the aldosterone and MR, and (2) how pharmacological manipulations of MR may affect ASUD-related outcomes. Our search in four databases (MEDLINE, Embase, Web of Science, and Cochrane Library) indicated that most studies focused on the relationship between aldosterone, MR, and alcohol (n = 30), with the rest focused on opioids (n = 5), nicotine (n = 9), and other addictive substances (n = 9). Despite some inconsistencies, the overall results suggest peripheral and central dysregulations of aldosterone and MR in several species and that these dysregulations depended on the pattern of drug exposure and genetic factors. We conclude that MR antagonism may be a promising target in ASUD, yet future studies are warranted.

Keywords: Alcohol; Aldosterone; Mineralocorticoid Receptor; Opioid; Spironolactone; Stimulants.

Publication types

  • Review

MeSH terms

  • Aldosterone* / pharmacology
  • Aldosterone* / physiology
  • Humans
  • Mineralocorticoid Receptor Antagonists / pharmacology
  • Receptors, Mineralocorticoid* / genetics
  • Spironolactone / pharmacology

Substances

  • Aldosterone
  • Receptors, Mineralocorticoid
  • Spironolactone
  • Mineralocorticoid Receptor Antagonists